Curis, Inc.CRISNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Loading chart...

Alerts

Want to monitor CRIS?

Get notified when price crosses targets, volume spikes, or RSI hits oversold

Create free account to monitor CRIS

Key Statistics

About

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology.

Sector

Professional, Scientific, and Technical Services

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

CEO

James Dentzer

curis.com/ →

S&P 500 Declines For Third Consecutive Session But Records Gain In January: Investor Sentiment Declines, Fear Index Remains In 'Greed' Zone

benzinga.com

Sanofi's genetic disorder drug shows mixed results in late-stage trials

reuters.com

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

benzinga.com

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

globenewswire.com

Shareholders Alert: Investigation Into Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky to Protect Your Rights

newsfilecorp.com

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Alerts

Key Statistics

About

News

EV maker Polestar secures $400 million equity funding

CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)

Julius Baer reports net profit of $988 million for 2025

Abercrombie & Fitch: Pullback Creates Another Opportunity

Exclusive: Barry Callebaut CEO left after high-level split over cocoa, sources say

S&P 500 Declines For Third Consecutive Session But Records Gain In January: Investor Sentiment Declines, Fear Index Remains In 'Greed' Zone

Sanofi's genetic disorder drug shows mixed results in late-stage trials

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

Chewy vs. Walmart: Which Is the Better Way to Invest in Pet Spending?​

Millicom International Cellular: The Turnaround Is Over - The Cash Flow Rerating Begins

Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy

Natural Gas Falls On Warmer Outlook: Should You Buy the Dip?

Alibaba to spend $431 million for Lunar New Year AI push as chatbot war heats up

This $25 Stock Could Be Your Ticket to Millionaire Status

Shareholders Alert: Investigation Into Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky to Protect Your Rights

Did You Suffer Losses in First Western Financial, Inc. (MYFW)? Contact Levi & Korsinsky About Securities Fraud Claims

Lost Money on REGENXBIO Inc. (RGNX)? Possible Fraud - Contact Levi & Korsinsky Today

Did You Suffer Losses in Bgin Blockchain Limited (BGIN)? Contact Levi & Korsinsky About Securities Fraud Claims

Tsodilo Resources Limited Closes Private Placement Financing for Units

Explore More

Key Statistics

EV maker Polestar secures $400 million equity funding

CROSSJECT announces initiation of coverage of its stock by Portzamparc (BNP Paribas Group)

Julius Baer reports net profit of $988 million for 2025

Abercrombie & Fitch: Pullback Creates Another Opportunity

Exclusive: Barry Callebaut CEO left after high-level split over cocoa, sources say

S&P 500 Declines For Third Consecutive Session But Records Gain In January: Investor Sentiment Declines, Fear Index Remains In 'Greed' Zone

Sanofi's genetic disorder drug shows mixed results in late-stage trials

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026

Chewy vs. Walmart: Which Is the Better Way to Invest in Pet Spending?​

Millicom International Cellular: The Turnaround Is Over - The Cash Flow Rerating Begins

Nuvation Bio: Rollout Data Of Ibtrozi Support A Modest Buy

Natural Gas Falls On Warmer Outlook: Should You Buy the Dip?

Alibaba to spend $431 million for Lunar New Year AI push as chatbot war heats up

This $25 Stock Could Be Your Ticket to Millionaire Status

Shareholders Alert: Investigation Into Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky to Protect Your Rights

Did You Suffer Losses in First Western Financial, Inc. (MYFW)? Contact Levi & Korsinsky About Securities Fraud Claims

Lost Money on REGENXBIO Inc. (RGNX)? Possible Fraud - Contact Levi & Korsinsky Today

Did You Suffer Losses in Bgin Blockchain Limited (BGIN)? Contact Levi & Korsinsky About Securities Fraud Claims

Tsodilo Resources Limited Closes Private Placement Financing for Units

Chewy vs. Walmart: Which Is the Better Way to Invest in Pet Spending?

Chewy vs. Walmart: Which Is the Better Way to Invest in Pet Spending?